AU2007300663A1 - Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions - Google Patents
Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions Download PDFInfo
- Publication number
- AU2007300663A1 AU2007300663A1 AU2007300663A AU2007300663A AU2007300663A1 AU 2007300663 A1 AU2007300663 A1 AU 2007300663A1 AU 2007300663 A AU2007300663 A AU 2007300663A AU 2007300663 A AU2007300663 A AU 2007300663A AU 2007300663 A1 AU2007300663 A1 AU 2007300663A1
- Authority
- AU
- Australia
- Prior art keywords
- epitope
- polynucleotide
- hla
- epitopes
- htl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83211206P | 2006-07-21 | 2006-07-21 | |
US60/832,112 | 2006-07-21 | ||
PCT/US2007/016529 WO2008039267A2 (fr) | 2006-07-21 | 2007-07-23 | Induction de réponses immunes cellulaires au virus de la grippe grâce à des compositions de peptides et d'acides nucléiques |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2007300663A1 true AU2007300663A1 (en) | 2008-04-03 |
Family
ID=39230737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007300663A Abandoned AU2007300663A1 (en) | 2006-07-21 | 2007-07-23 | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2069376A4 (fr) |
AU (1) | AU2007300663A1 (fr) |
CA (1) | CA2658559A1 (fr) |
WO (1) | WO2008039267A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103333224A (zh) * | 2013-05-10 | 2013-10-02 | 中国农业科学院哈尔滨兽医研究所 | 禽流感病毒ns1蛋白b细胞抗原表位多肽及其应用 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101660363B1 (ko) | 2007-06-25 | 2016-09-28 | 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 | 인플루엔자를 억제하는 조성물 및 방법 |
CA2695399C (fr) * | 2007-08-02 | 2017-10-17 | Biondvax Pharmaceuticals Ltd. | Vaccins contre la grippe a multiples epitopes multimeres |
EP2296688A2 (fr) * | 2007-10-26 | 2011-03-23 | Glykos Finland Oy | Vaccin peptidique contre le virus de la grippe |
FI20080333A0 (fi) * | 2008-05-02 | 2008-05-02 | Glykos Finland Oy | Influenssaviruksen nukleiinihappoja ja peptidejä |
CA2744348C (fr) * | 2008-11-19 | 2017-02-14 | Laboratorio Avi-Mex, S.A. De C.V. | Vaccin recombinant a vecteur viral inactive |
US8282938B2 (en) | 2008-11-28 | 2012-10-09 | National Institute Of Infectious Diseases | Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain |
WO2010086294A2 (fr) | 2009-01-28 | 2010-08-05 | Epimmune Inc. | Polypeptides de liaison de pan-dr et leurs utilisations |
US20100310591A1 (en) * | 2009-01-28 | 2010-12-09 | Robert Humphreys | Ii-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA |
CN101792745B (zh) * | 2009-02-04 | 2014-09-17 | 中国科学院生物物理研究所 | 流感病毒聚合酶亚基pa氨基端多肽的表达纯化及pa氨基端多肽的晶体结构 |
CN101565455B (zh) * | 2009-05-25 | 2012-03-14 | 中国科学院微生物研究所 | 禽流感h5n1病毒的ctl表位多肽及其应用 |
US8926982B2 (en) * | 2009-06-01 | 2015-01-06 | Xuguang Li | Reagents and methods for detecting influenza virus proteins |
BR112012008060A2 (pt) | 2009-07-31 | 2016-11-22 | Paxvax Inc | vetores baseados em adenovírus |
CA2775720A1 (fr) * | 2009-09-30 | 2011-04-07 | Saint Louis University | Peptides declenchant des reponses hetero sous-typiques des lymphocytes t contre la grippe |
CN102153621B (zh) * | 2010-02-12 | 2014-07-02 | 广东省疾病预防控制中心 | 新型甲型h1n1流感na蛋白b细胞表位及其应用 |
US9149025B2 (en) | 2010-02-19 | 2015-10-06 | Universite De Liege | Polynucleotide for use in treatment of influenza A virus induced diseases, encoding modified Mx protein, said modified Mx protein, and a transgenic animal expressing gene encoding modified Mx protein |
WO2011138032A2 (fr) * | 2010-05-05 | 2011-11-10 | Artemev, Timur | Vaccins antigrippaux universels et leurs procédés de production |
CN105061534A (zh) | 2010-09-22 | 2015-11-18 | 艾丽奥斯生物制药有限公司 | 取代的核苷酸类似物 |
CN103517713A (zh) | 2011-02-22 | 2014-01-15 | 彼昂德瓦克斯医药有限公司 | 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽 |
WO2013059403A1 (fr) * | 2011-10-19 | 2013-04-25 | Immunotope, Inc. | Immunogènes induisant des lymphocytes t cytotoxiques pour prévenir, traiter, et diagnostiquer l'infection par le virus de l'influenza |
AU2012358804B2 (en) | 2011-12-22 | 2018-04-19 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
WO2013093514A2 (fr) * | 2011-12-23 | 2013-06-27 | Retroscreen Virology Ltd | Vaccins - peptides |
US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
US20140193484A1 (en) * | 2013-01-10 | 2014-07-10 | Sylvie Carine Bertholet Girardin | Influenza virus immunogenic compositions and uses thereof |
WO2015186721A1 (fr) * | 2014-06-03 | 2015-12-10 | 国立研究開発法人農業・食品産業技術総合研究機構 | Anticorps ou fragment d'anticorps comprenant une région variable de celui-ci, polypeptide antigénique et utilisations de ceux-ci |
CN111148528A (zh) | 2016-12-28 | 2020-05-12 | 英福瓦克思公司 | 流感疫苗 |
CN106589105B (zh) * | 2017-01-23 | 2020-09-15 | 中国医科大学 | Hla-a2限制性ecm1特异性的ctl表位肽及其应用 |
EP3679056A1 (fr) * | 2017-09-08 | 2020-07-15 | The University of Melbourne | Procédés et compositions pour la prévention d'une infection grippale |
CN111315407B (zh) * | 2018-09-11 | 2023-05-02 | 上海市公共卫生临床中心 | 一种广谱抗流感疫苗免疫原及其应用 |
JP2023530135A (ja) * | 2020-06-19 | 2023-07-13 | インターベット インターナショナル ベー. フェー. | 特定のウイルス系統の抗原をエンコードする核酸構築物を含むブタインフルエンザaウイルスワクチン |
WO2021255225A1 (fr) * | 2020-06-19 | 2021-12-23 | Intervet International B.V. | Vaccin contre le virus de la grippe porcine comprenant une construction d'acide nucléique comprenant des première, deuxième et troisième séquences d'acide nucléique codant pour des antigènes de neuraminidase distincts du virus |
WO2022032274A1 (fr) * | 2020-08-02 | 2022-02-10 | Richard Ascione | Compositions de vaccins contre les virus de la grippe et méthodes d'utilisation |
TW202219062A (zh) * | 2020-08-25 | 2022-05-16 | 美商建南德克公司 | 用於特性化mhci肽結合的測定及試劑 |
CN116410271B (zh) * | 2023-03-13 | 2024-07-19 | 华南农业大学 | H5n1亚型aiv mhc b1限制性t细胞表位肽及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7572620B2 (en) * | 2005-01-11 | 2009-08-11 | Wisconsin Alumni Research Foundation | H3 equine influenza A virus |
-
2007
- 2007-07-23 CA CA002658559A patent/CA2658559A1/fr not_active Abandoned
- 2007-07-23 EP EP07861332.0A patent/EP2069376A4/fr not_active Withdrawn
- 2007-07-23 WO PCT/US2007/016529 patent/WO2008039267A2/fr active Application Filing
- 2007-07-23 AU AU2007300663A patent/AU2007300663A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103333224A (zh) * | 2013-05-10 | 2013-10-02 | 中国农业科学院哈尔滨兽医研究所 | 禽流感病毒ns1蛋白b细胞抗原表位多肽及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2008039267A2 (fr) | 2008-04-03 |
EP2069376A2 (fr) | 2009-06-17 |
WO2008039267A3 (fr) | 2008-12-31 |
CA2658559A1 (fr) | 2008-04-03 |
EP2069376A4 (fr) | 2013-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007300663A1 (en) | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions | |
DK2023952T3 (en) | Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions | |
KR101983989B1 (ko) | 인플루엔자 바이러스 백신 및 이의 용도 | |
KR101736897B1 (ko) | 인플루엔자 항원 수송 벡터 및 구조물 | |
JP2023524054A (ja) | ベータコロナウイルスの予防と治療 | |
CN112469661A (zh) | 具有新结构组分的纳米粒疫苗 | |
Sharma et al. | A self-adjuvanted, modular, antigenic VLP for rapid response to influenza virus variability | |
CN105473604A (zh) | 融合前rsv f蛋白和其用途 | |
AU2007213562A2 (en) | Peptide sequences and compositions | |
JP2010535026A (ja) | 多量体マルチエピトープインフルエンザワクチン | |
Reginald et al. | Development of peptide vaccines in dengue | |
US9963490B2 (en) | Influenza nucleoprotein vaccines | |
Frangione-Beebe et al. | Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide | |
McMurry et al. | A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A | |
US9896484B2 (en) | Influenza virus recombinant proteins | |
WO2020041311A1 (fr) | Vecteurs pour induire des réponses immunitaires à des épitopes non dominants dans la protéine hémagglutinine (ha) | |
Sia et al. | Engineered nanoparticle applications for recombinant influenza vaccines | |
JP2023534840A (ja) | M2/bm2欠失インフルエンザベクターを使用したワクチン | |
RU2358981C2 (ru) | Универсальная вакцина против вируса гриппа птиц | |
Naskalska et al. | Influenza recombinant vaccine: matrix protein M1 on the platform of the adenovirus dodecahedron | |
JP2022553258A (ja) | インフルエンザウイルスワクチン及びその使用 | |
Skarlas et al. | Influenza virus H5N1 hemagglutinin (HA) T‐cell epitope conjugates: design, synthesis and immunogenicity | |
Park et al. | Development of Self-Assembled Protein Nanocage Spatially Functionalized with HA Stalk as a Broadly Cross-Reactive Influenza Vaccine Platform | |
WO2020086927A1 (fr) | Peptides pour induire des réponses hétérosubtypiques de lymphocytes t de la grippe | |
EA046906B1 (ru) | Вакцины против вируса гриппа и пути их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |